Search

Lasmiditan

other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without … [A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT_1D and 5-HT_1B receptors, and activity at the 5-HT_1B receptor has been specifically

Levosimendan

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Simeprevir

This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. … Administered once daily with food, 150mg simeprevir capsule is used in combination with [DB08934] in patients with HCV genotype 1 without cirrhosis for 12 week duration.

Methylnaltrexone

Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.

Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine

Rimegepant

[L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.

Tasonermin

It is administered with [DB01042] via mild hyperthermic isolated limb perfusion. … Tasonermin is recombinant soluble form tumor necrosis factor α produced via _Escherichia coli_ cell culture.

Berahyaluronidase alfa

This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications … previously only available via intravenous administration, including melanoma, non-small cell lung cancer, and urothelial cancer.